The Cholesterol Debate Is Asking the Wrong Question

Editorial Transparency: HormoneSynergy® has no financial relationship with the physicians, podcasts or publications discussed in this article. This is an independent editorial review of cardiovascular and longevity claims using published research and current clinical guidance. It is educational and is not individualized medical advice.

A Heart Surgeon Makes an Important Point

There is something compelling about hearing a heart surgeon say that too many patients reach the operating room after years of preventable metabolic deterioration.

That part deserves attention.

Coronary disease does not suddenly appear the week someone develops chest pain. Insulin resistance, rising blood pressure, visceral fat accumulation, worsening glucose control, smoking, inactivity and other risk factors can develop quietly for years while conventional laboratory values still look relatively reassuring.

This is one reason we spend so much time talking about metabolic health in longevity medicine. Waiting for diabetes or symptomatic cardiovascular disease before becoming interested in insulin resistance is waiting too long.

Where the argument becomes less convincing is the suggestion that recognizing metabolic disease requires rejecting the importance of cholesterol.

It does not.

Metabolic Health and ApoB Are Not Competing Theories

The familiar phrase “cholesterol causes heart disease” is admittedly imprecise. Cholesterol itself is essential biology. The more useful cardiovascular question concerns the particles transporting cholesterol through the circulation, particularly ApoB-containing lipoproteins.

ApoB provides an estimate of the number of atherogenic particles capable of entering and becoming retained within the arterial wall. Decades of evidence from human genetics, Mendelian randomization, pathology and lipid-lowering trials support a causal role for these particles in atherosclerotic cardiovascular disease.

The European Atherosclerosis Society summarized that evidence years ago, and contemporary cardiovascular guidance continues to move toward broader use of ApoB rather than abandoning lipid biology. The 2026 ACC/AHA dyslipidemia guidance specifically expanded the role of ApoB and also recommends broader recognition of particle-based cardiovascular risk.

That does not make insulin resistance irrelevant. Quite the opposite. Metabolic dysfunction can increase triglyceride-rich particles, alter lipoprotein composition, raise blood pressure, promote visceral adiposity and contribute to the inflammatory environment in which cardiovascular disease progresses.

These processes interact.

A metabolically healthy person can still have substantial inherited cardiovascular risk from familial hypercholesterolemia or elevated Lp(a). A person with seemingly acceptable LDL-C can still have significant ApoB burden, insulin resistance, hypertension or existing coronary plaque.

Choosing one story and ignoring the other is not more sophisticated medicine.

The Red-Meat History Is Not as Simple as It Sounds

Another popular argument goes something like this: Americans dramatically reduced red-meat consumption while heart disease became more common, therefore red meat cannot be responsible for cardiovascular disease.

The historical record is considerably messier.

USDA data show that beef consumption increased during much of the postwar period and reached its peak in 1976 at approximately 88.8 pounds available per person before subsequently declining. There was no simple, uninterrupted 40-percent decline beginning in the 1950s.

The heart-disease side of the comparison is also problematic. CDC data show that age-adjusted death rates from diseases of the heart fell dramatically during the second half of the twentieth century. The rate declined from 307.4 deaths per 100,000 people in 1950 to 134.6 in 1996, a 56-percent reduction.

Heart disease remains enormously important, and population aging means large numbers of Americans still live with cardiovascular disease. That is different from saying heart disease simply worsened while Americans stopped eating beef.

There is also an odd methodological problem with using those trends as proof. If observational nutrition research is considered unreliable because it cannot adequately separate diet from smoking, exercise, income and other behaviors, comparing national meat consumption with national heart-disease trends has exactly the same problem, only on a much larger scale.

Nutrition Epidemiology Deserves Criticism

This does not mean the criticism of nutrition research is wrong.

Long-term dietary research is difficult. Researchers cannot realistically randomize thousands of people to eat one diet for thirty years while controlling everything else they do. Much of what we know about long-term nutrition therefore comes from observational cohorts, dietary questionnaires and epidemiology.

Those methods have limitations. People who eat differently often behave differently in other ways. Smoking, alcohol use, physical activity, body weight, socioeconomic status and healthcare use can travel together with dietary choices.

Randomized trials of red meat also produce a more complicated picture than social-media arguments from either side suggest. A recent network meta-analysis of randomized trials found that cardiovascular effects depended heavily on what replaced the red meat. Substitution with higher-quality plant protein sources produced more favorable changes in total and LDL cholesterol, although the overall certainty of evidence was rated low or very low.

That replacement question matters. Removing steak and replacing it with lentils, nuts and fish is not metabolically equivalent to replacing it with refined starch and ultra-processed food.

We do not need to turn beef into either a poison or a health food to acknowledge that distinction.

The NAD Claim Has a Similar Problem

The discussion then moves from cardiovascular disease to NAD supplementation, where another reasonable criticism gets stretched too far.

Human evidence for NAD-related longevity interventions remains much less impressive than the marketing surrounding them. That is a fair criticism.

A 2026 systematic review examining NAD augmentation in humans concluded that these interventions demonstrate biological activity while clinical effectiveness for anti-aging and wellness outcomes remains uncertain.

That is not the same as showing that oral NAD supplements or precursors simply “do not raise blood NAD.”

The terminology matters. NAD+, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are not interchangeable products. NR and NMN are precursors used by the body in NAD metabolism, and human studies have demonstrated changes in NAD-related biomarkers following supplementation. Some NMN trials have specifically reported increases in blood NAD concentrations.

The unanswered question is much more interesting: does increasing those biomarkers lead to clinically meaningful improvements in strength, cognition, metabolic health, disease prevention or lifespan?

So far, the evidence is far less convincing.

This is a recurring problem in longevity medicine. Demonstrating that a supplement changes a pathway is relatively easy. Demonstrating that changing the pathway meaningfully improves human health is much harder.

Measure the Patient, Not the Diet Tribe

There is one part of the heart surgeon's argument that we strongly agree with: a dietary strategy should eventually answer to physiology.

A person can call a diet Mediterranean, ketogenic, carnivore, vegan, low-fat or ancestral. The name does not tell us what is happening to that person's cardiovascular or metabolic risk.

We would rather know what happened to blood pressure, fasting insulin, glucose regulation, triglycerides, ApoB, Lp(a), visceral fat, lean mass and inflammatory markers. When appropriate, we also want to know whether arterial plaque is actually present.

That is why cardiovascular prevention at HormoneSynergy® is not built around a “cholesterol-only” model, but it is certainly not built around a “cholesterol-doesn't-matter” model either. We have written more extensively about that distinction in Cholesterol Controversy, ApoB, and Heart Disease Risk.

What We Would Rather Know

A perfect fasting glucose does not tell us whether someone has coronary plaque. A favorable LDL-C does not tell us everything about particle number. A low triglyceride level does not erase a markedly elevated Lp(a). Good insulin sensitivity does not make familial hypercholesterolemia disappear.

The reverse is also true. A lipid panel alone does not tell us whether visceral fat is accumulating, insulin is rising, blood pressure is drifting upward or skeletal muscle is being lost.

The point of preventive medicine is not to find the biomarker that proves our preferred theory correct. It is to identify the risk that matters in the person sitting in front of us while there is still time to change the trajectory.

For a broader look at how these systems fit together, see What Actually Moves Longevity Metrics. Our Optimal Aging Assessment approaches cardiovascular risk as part of a larger clinical picture that includes metabolic health, body composition, cognition, hormones and other drivers of healthspan.

When the clinical question is specifically whether coronary plaque is already present, anatomical imaging can add information that another blood test cannot. We discuss that distinction in Optimal Aging Assessment vs. Cleerly® Testing.

The HormoneSynergy® Perspective

The cholesterol-versus-metabolism debate makes for good podcasts because it gives everyone a side.

It makes considerably less sense in a preventive medicine clinic.

Metabolic health matters. ApoB matters. Blood pressure matters. Smoking matters. Lp(a) matters. Body composition matters. Family history matters. Existing plaque matters.

Good cardiovascular medicine does not require us to decide which one gets to be the cause.

It requires us to figure out which ones are creating risk in this patient.

Medicine, Not Marketing.

Frequently Asked Questions

Is metabolic health more important than cholesterol for heart disease?

They should not be treated as competing risk models. Insulin resistance, visceral adiposity, hypertension and abnormal glucose regulation can substantially increase cardiovascular risk, while ApoB-containing lipoproteins have strong causal evidence in atherosclerosis. A comprehensive assessment considers both.

Does a normal LDL cholesterol level mean cardiovascular risk is low?

Not necessarily. LDL-C measures the cholesterol carried within LDL particles rather than the total number of atherogenic particles. ApoB, Lp(a), blood pressure, metabolic health, family history and evidence of plaque can provide additional information.

Does red meat cause heart disease?

The relationship is more complicated than either “red meat causes heart disease” or “red meat is harmless.” Observational studies have limitations, randomized trials often examine intermediate risk markers rather than cardiovascular events, and the food replacing red meat can materially affect the result.

Do NR and NMN raise NAD?

Human studies indicate that oral NAD precursors such as NR and NMN can alter NAD-related biomarkers, and some NMN trials have demonstrated increased blood NAD concentrations. Whether those biochemical changes translate into meaningful anti-aging or longevity benefits remains uncertain.

What cardiovascular markers does HormoneSynergy® consider?

Evaluation is individualized but may include standard lipids, ApoB, Lp(a), triglycerides, glucose and insulin regulation, inflammation, blood pressure, body composition and cardiovascular imaging when clinically appropriate.

Selected References

Centers for Disease Control and Prevention. Decline in Deaths from Heart Disease and Stroke — United States, 1900–1999.

USDA Economic Research Service. U.S. Per Capita Availability of Red Meat, Poultry, and Fish/Shellfish.

Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: evidence from genetic, epidemiologic, and clinical studies. European Heart Journal.

Borén J, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights. European Heart Journal.

López-Moreno M, et al. Effect of red meat consumption on cardiovascular risk factors: a systematic review and network meta-analysis of randomized controlled trials.

Gallagher C, Emmanuel C. NAD+ supplementation for anti-aging and wellness: a systematic review of human clinical studies.

Yi L, et al. The efficacy and safety of β-nicotinamide mononucleotide supplementation in healthy middle-aged adults.